Wave Life Sciences Ltd.NASDAQ: WVE

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

· Issued by Wave Life Sciences Ltd.
Watch Wave Life Sciences explain itWave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call · Replay · Jul 30

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p

Company analysis